Physician profile
Rameshkumar K Raman
NPI 1376521484
$103,378.23
in general payments reported to CMS, 2019-2025
44 companies · $860 in 2025
The $860 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $13K · 2021: $14K · 2022: $36K · 2023: $9,529 · 2024: $544 · 2025: $860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,988 · Food and Beverage: $2,933 · Travel and Lodging: $13.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,988.00 |
| Food and Beverage | $2,932.55 |
| Travel and Lodging | $13.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $55,981.67 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $17,766.56 | 2019-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $16,743.92 | 2021-2025 | |
| Dexcom, INC. | $4,540.29 | 2019-2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $2,581.34 | 2019-2025 | |
| Amgen INC. | $818.61 | 2019-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $631.36 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Abbott Laboratories | $615.32 | 2019-2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $432.45 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Sanofi-Aventis U.S. LLC | $334.53 | 2019-2023 | |
| Tandem Diabetes Care, INC. | $287.11 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Merck Sharp & Dohme LLC | $281.99 | 2019-2022 | |
| Medtronic, INC. | $235.53 | 2022-2024 | Minimed 780g |
| Corcept Therapeutics | $171.12 | 2019-2023 | Korlym |
| Novartis Pharmaceuticals Corporation | $168.54 | 2022-2023 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $163.63 | 2019-2023 | Tepezza |
| Radius Health, INC. | $146.17 | 2019-2025 | Tymlos |
| Xeris Pharmaceuticals, INC. | $129.69 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Bigfoot Biomedical INC | $114.98 | 2022-2023 | Unity Diabetes Management System |
| Ascensia Diabetes Care US INC. | $105.60 | 2024-2025 | |
| Sequel Med Tech, LLC | $95.19 | 2025 | Twiist |
| Antares Pharma, INC. | $88.41 | 2022-2025 | Xyosted |
| Valeritas, INC. | $85.60 | 2019 | |
| Janssen Pharmaceuticals, INC | $77.20 | 2019-2020 | |
| Medtronic Minimed, INC. | $75.39 | 2019 | |
| Amarin Pharma, INC. | $73.99 | 2019-2021 | |
| Shire North American Group INC | $68.48 | 2019 | |
| Insulet Corporation | $65.66 | 2019-2024 | Omnipod |
| Regeneron Healthcare Solutions, INC. | $64.00 | 2019 | |
| Alexion Pharmaceuticals, INC. | $50.02 | 2021-2023 | Strensiq |
| Kowa Pharmaceuticals America, INC. | $49.98 | 2020-2021 | |
| Almatica Pharma LLC | $43.88 | 2025 | Teriparatide |
| Mannkind Corporation | $41.99 | 2022-2023 | Afrezza |
| Ascendis Pharma Endocrinology INC | $38.55 | 2025 | Yorvipath |
| Amryt Pharma Holdings LTD | $33.88 | 2022-2023 | Mycapssa |
| Halozyme INC | $33.37 | 2023 | |
| Sandoz INC. | $22.34 | 2025 | Hyrimoz |
| Companion Medical, INC. | $22.16 | 2019 | |
| Beta Bionics, INC. | $20.60 | 2024 | Ilet Bionic Pancreas |
| Madrigal Pharmaceuticals | $19.25 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $15.78 | 2020 | |
| Chiesi USA, INC. | $15.26 | 2024 | Mycapssa |
| Ibsa Pharma INC. | $14.74 | 2021 | |
| Currax Pharmaceuticals LLC | $12.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rameshkumar Raman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.